Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C10H15N3.H2O4S |
Molecular Weight | 452.571 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.CNC(NC)=NCC1=CC=CC=C1.CNC(NC)=NCC2=CC=CC=C2
InChI
InChIKey=YTIJUXVIZLYQTB-UHFFFAOYSA-N
InChI=1S/2C10H15N3.H2O4S/c2*1-11-10(12-2)13-8-9-6-4-3-5-7-9;1-5(2,3)4/h2*3-7H,8H2,1-2H3,(H2,11,12,13);(H2,1,2,3,4)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/6065986
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6065986
Bethanidine is a post-ganglionic adrenergic neurone-blocking agent which exerts a marked postural hypotensive effect. The precise mechanism whereby bethanidine causes blockade of adrenergic neurones is unknown. An initial sympathomimetic effect has been demonstrated in man and animals, possibly due to release of catecholamines.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6232
Curator's Comment: Whole body autoradiograms showed a high concentration of drug in rat tissues rich in adrenergic nerve terminals, but insignificant penetration, if any, of the blood-brain barrier.
Originator
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1120401/ |
25 mg single, intravenous dose: 25 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
BETHANIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1120401/ |
25 mg single, intravenous dose: 25 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
BETHANIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1120401/ |
25 mg single, intravenous dose: 25 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
BETHANIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
90% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1120401/ |
25 mg single, intravenous dose: 25 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
BETHANIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Side effects of hypotensive agents evaluated by a self-administered questionnaire. | 1973 Sep 1 |
|
Do antihypertensive drugs really cause depression? | 1974 Sep |
|
Factors predisposing to postural hypotensive symptoms in the treatment of high blood pressure. | 1975 Oct |
|
Dihydroergotamine: an effective treatment for postural hypotension due to antihypertensive drugs (ganglion-blocking agents excepted). | 1976 |
|
Exertional hypotension due to postganglionic sympathetic blocking drugs. | 1976 Aug |
|
Patterns of blood-pressure during chronic administration of postganglionic sympathetic blocking drugs for hypertension. | 1976 Nov 13 |
|
Antiarrhythmic action of bethanidine. | 1984 Aug 1 |
|
Antiarrhythmic and electrophysiologic actions of bethanidine sulfate in primary ventricular fibrillation or life-threatening ventricular tachycardia. | 1984 May 1 |
|
Acute electrophysiologic effects of bethanidine sulfate in patients with ventricular tachycardia or fibrillation. | 1984 Nov |
|
The aggressive treatment of hypertension. | 2003 May 3 |
|
eCAM benefits from diversity that derives from CAM. | 2005 Sep |
|
Treatment outcome in patients receiving assertive community treatment. | 2010 Aug |
Sample Use Guides
Initial therapy 0.228 mg/kg 8 hourly
Maintenance therapy 0.114 to 0.228 mg/kg 8 hourly
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3383015
The effects of bethanidine sulphate, a pharmacological analog of the cardiac antibrillatory drug, bretylium tosylate, were studied on action potentials (APs) and K+, Na+, and Ca2+ currents of single cultured embryonic chick heart cells using the whole-cell current clamp and voltage clamp technique. Extracellular application of bethanidine (0.3 mM) increased the overshoot and the duration of the APs and greatly decreased the outward K+ current (IK) and potentiated the inward fast Na+ currents (INa) and the inward slow calcium current (ICa). However, intracellular introduction of bethanidine (0.1 mM) blocked INa.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C72900
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
||
|
NCI_THESAURUS |
C270
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
||
|
FDA ORPHAN DRUG |
26087
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
||
|
FDA ORPHAN DRUG |
32588
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1201260
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
114-85-2
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
106563
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
8248
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
J4THI5N7O2
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
100000085023
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
81966
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | RxNorm | ||
|
DBSALT000194
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
m2458
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB00787MIG
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
31279
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
204-056-9
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
DTXSID7048748
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
C65260
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD